Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with concurrent IMRT for recurrent nasopharyngeal carcinoma
ChiCTR-ONC-14004561Phase 2Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Disease control rate and Safety. Started Mar 2014; status: completed.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-ONC-14004561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-14004561.